ammonium hydroxide has been researched along with Cardiomyopathies in 18 studies
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Isoproterenol-induced necrosis of the heart muscle leads to a decrease in both glutamine and alanine ability to bind ammonia (20--40 and 30--45%, respectively)." | 3.66 | [Neutralization of ammonia in cardiac muscle]. ( Minkovskiĭ, EB; Pisarenko, OI; Studneva, IM, 1980) |
| "VPA is widely used for the treatment of generalized epilepsy." | 2.61 | [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. ( Araki, M; Mukai, T; Naka, H; Shishido, T; Tokinobu, H; Yamada, H, 2019) |
| "Systemic sarcoidosis was diagnosed by histologically proven noncaseating epithelioid granuloma, and cardiac sarcoidosis was diagnosed according to the Japanese Ministry of Health and Welfare guidelines for diagnosing cardiac sarcoidosis." | 1.32 | Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. ( Akioka, K; Shirai, N; Takagi, M; Takeuchi, K; Yamagishi, H; Yoshikawa, J; Yoshiyama, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Weber, B | 1 |
| Parks, S | 1 |
| Huck, DM | 1 |
| Kim, A | 1 |
| Bay, C | 1 |
| Brown, JM | 1 |
| Divakaran, S | 1 |
| Hainer, J | 1 |
| Bibbo, C | 1 |
| Taqueti, V | 1 |
| Dorbala, S | 1 |
| Blankstein, R | 1 |
| Woolley, AE | 1 |
| Di Carli, MF | 1 |
| Miura, S | 1 |
| Okizaki, A | 1 |
| Manabe, O | 1 |
| Miyazaki, C | 1 |
| Yamashita, T | 1 |
| Toma, L | 1 |
| Stanciu, AM | 1 |
| Zgura, A | 1 |
| Bacalbasa, N | 1 |
| Diaconu, C | 1 |
| Iliescu, L | 1 |
| Wang, JZ | 1 |
| Zelt, JGE | 1 |
| Kaps, N | 1 |
| Lavallee, A | 1 |
| Renaud, JM | 1 |
| Rotstein, B | 1 |
| Beanlands, RSB | 1 |
| Fallavollita, JA | 1 |
| Canty, JM | 2 |
| deKemp, RA | 1 |
| Yamada, H | 1 |
| Shishido, T | 1 |
| Mukai, T | 1 |
| Araki, M | 1 |
| Naka, H | 1 |
| Tokinobu, H | 1 |
| Lang, JK | 1 |
| Gonzalez, WO | 1 |
| Massera, D | 1 |
| Travin, MI | 1 |
| Kruse, MJ | 1 |
| Kovell, L | 1 |
| Kasper, EK | 1 |
| Pomper, MG | 1 |
| Moller, DR | 1 |
| Solnes, L | 1 |
| Chen, ES | 1 |
| Schindler, TH | 1 |
| Chen, S | 1 |
| Bokhari, S | 1 |
| Yoon, YA | 1 |
| Lee, DH | 1 |
| Ki, CS | 1 |
| Lee, SY | 1 |
| Kim, JW | 1 |
| Lee, YW | 1 |
| Park, HD | 1 |
| Himi, T | 1 |
| Masuda, Y | 1 |
| Yamagishi, H | 1 |
| Shirai, N | 1 |
| Takagi, M | 1 |
| Yoshiyama, M | 1 |
| Akioka, K | 1 |
| Takeuchi, K | 1 |
| Yoshikawa, J | 1 |
| Steinmetz, AP | 1 |
| Maisey, MN | 1 |
| Hardoff, R | 1 |
| Morita, H | 1 |
| Yokoyama, I | 1 |
| Yamada, N | 1 |
| Uno, K | 1 |
| Nagai, R | 1 |
| Pisarenko, OI | 1 |
| Minkovskiĭ, EB | 1 |
| Studneva, IM | 1 |
| Niemeyer, MG | 1 |
| Kuijper, AF | 1 |
| Meeder, JG | 1 |
| Cramer, MJ | 1 |
| Cleophas, AJ | 1 |
| van der Wall, EE | 1 |
| Kaltoft, A | 1 |
| Bøttcher, M | 1 |
| Sand, NP | 1 |
| Flø, C | 1 |
| Nielsen, TT | 1 |
| Rehling, M | 1 |
| Fudo, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Application of Total-body 13N-NH3 PET/CT to Study the Blood Perfusion System in the Whole Body[NCT04941248] | 16 participants (Anticipated) | Observational | 2021-06-27 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ammonium hydroxide and Cardiomyopathies
| Article | Year |
|---|---|
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Topics: Aged; Ammonia; Anticonvulsants; Biomarkers; Cardiomyopathies; Carnitine; Consciousness Disorders; Ep | 2019 |
[Nitrogen-13 ammonia positron emission tomography--myocardial perfusion imaging].
Topics: Ammonia; Cardiomyopathies; Coronary Circulation; Heart; Humans; Myocardial Ischemia; Nitrogen Radioi | 1994 |
Comparison of thallium scintigraphy and positron emission tomography.
Topics: Ammonia; Cardiomyopathies; Coronary Circulation; Coronary Disease; Cost-Benefit Analysis; Fluorodeox | 1997 |
15 other studies available for ammonium hydroxide and Cardiomyopathies
| Article | Year |
|---|---|
Prior SARS-CoV-2 Infection Is Associated With Coronary Vasomotor Dysfunction as Assessed by Coronary Flow Reserve From Cardiac Positron Emission Tomography.
Topics: Ammonia; Cardiomyopathies; Coronary Artery Disease; Coronary Circulation; COVID-19; Female; Fraction | 2022 |
Serial Quantitative Assessment of Myocardial Blood Flow With
Topics: Ammonia; Cardiomyopathies; Coronary Circulation; Heart Failure; Humans; Myocardial Perfusion Imaging | 2023 |
Electrocardiographic Changes in Liver Cirrhosis-Clues for Cirrhotic Cardiomyopathy.
Topics: Ammonia; Cardiomyopathies; Cholesterol; Chronic Disease; Electrocardiography; Female; Hepatitis, Vir | 2020 |
Does quantification of [
Topics: Ammonia; Cardiomyopathies; Death, Sudden, Cardiac; Ephedrine; Heart; Humans; Kinetics; Myocardial Is | 2022 |
The complexity of using resting myocardial perfusion to assess myocardial viability and predict functional recovery.
Topics: Ammonia; Cardiomyopathies; Humans; Nitrogen Radioisotopes; Perfusion | 2021 |
False-positive (13)N-ammonia/(18)FDG PET for evaluation of cardiac sarcoidosis in a patient on peritoneal dialysis.
Topics: Ammonia; Cardiomyopathies; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Male; Middle Ag | 2015 |
Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis.
Topics: Ammonia; Blood Flow Velocity; Cardiomyopathies; Coronary Circulation; Female; Fluorodeoxyglucose F18 | 2017 |
Diagnosis of cardiac sarcoidosis through mismatched defects seen on N-13 NH3/F-18 FDG cardiac PET.
Topics: Ammonia; Cardiomyopathies; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nitrogen Radioisotopes | 2011 |
SLC22A5 mutations in a patient with systemic primary carnitine deficiency: the first Korean case confirmed by biochemical and molecular investigation.
Topics: Ammonia; Base Sequence; Cardiomyopathies; Carnitine; Humans; Hyperammonemia; Infant, Newborn; Lactic | 2012 |
Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET.
Topics: Adult; Aged; Ammonia; Carbon Isotopes; Cardiomyopathies; Female; Fluorodeoxyglucose F18; Heart; Huma | 2003 |
Patterns of papillary muscle ischemia in myocardial PET.
Topics: Ammonia; Cardiomyopathies; Female; Fluorodeoxyglucose F18; Heart Failure; Humans; Male; Middle Aged; | 2004 |
Usefulness of 18FDG/13N-ammonia PET imaging for evaluation of the cardiac damage in Churg-Strauss syndrome.
Topics: Ammonia; Cardiomyopathies; Churg-Strauss Syndrome; Female; Fluorodeoxyglucose F18; Humans; Middle Ag | 2004 |
[Neutralization of ammonia in cardiac muscle].
Topics: Alanine; Ammonia; Animals; Aspartic Acid; Cardiomyopathies; Glutamates; Glutamine; Isoproterenol; Ma | 1980 |
99mTc-Sestamibi SPECT is a useful technique for viability detection: results of a comparison with NH3/FDG PET.
Topics: Adult; Aged; Ammonia; Cardiomyopathies; Cell Survival; Coronary Angiography; Coronary Artery Disease | 2001 |
[Myocardial blood flow imaging of cardiomyopathy with N-13 ammonia].
Topics: Ammonia; Cardiomyopathies; Coronary Circulation; Heart; Humans; Nitrogen Radioisotopes; Tomography, | 1991 |